Literature DB >> 28971862

Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.

Sonya A Trinh1, Hannah E Gavin2, Karla J F Satchell3.   

Abstract

Foodborne Vibrio vulnificus infections are associated with higher rates of sepsis and mortality than wound infections; however, antibiotic efficacy studies have not been performed in foodborne infection models. The efficacies of ceftriaxone, cefepime, doxycycline, ciprofloxacin, and combination therapy were assessed in V. vulnificus intestinal infection in mice in order to model foodborne infections. In accordance with prior studies of cefotaxime, cefepime was synergistic with doxycycline and ciprofloxacin in vitro; combination therapy significantly decreased bacterial growth, by ≥2 log10 units, from that with antibiotic monotherapy (P < 0.01). In vivo, survival rates in the ceftriaxone (50%), doxycycline (79%), and ciprofloxacin (80%) groups were significantly higher than those in the control group (0%) (P < 0.0001). Survival was significantly higher with ceftriaxone-doxycycline (91%) or ceftriaxone-ciprofloxacin (100%) therapy than with ceftriaxone (50%) (P ≤ 0.05). Survival with cefepime-doxycycline (96%) or cefepime-ciprofloxacin (90%) therapy was significantly higher than that with cefepime alone (20%) (P < 0.001). There was no difference in survival between the combination therapy groups. Thus, we conclude that combination therapy was the most effective treatment for foodborne V. vulnificus septicemia. In a septic patient with a recent ingestion of raw seafood, cefepime in combination with doxycycline or ciprofloxacin should be initiated for coverage of resistant Gram-negative organisms and V. vulnificus pending a microbiological diagnosis. Once a diagnosis of foodborne V. vulnificus septicemia is established, treatment can safely transition to ceftriaxone in combination with doxycycline or ciprofloxacin.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Vibrio vulnificus; cefepime; ceftriaxone; ciprofloxacin; doxycycline; foodborne infection; foodborne septicemia; mouse

Mesh:

Substances:

Year:  2017        PMID: 28971862      PMCID: PMC5700324          DOI: 10.1128/AAC.01106-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  34 in total

1.  In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.

Authors:  Hung-Jen Tang; Ming-Chung Chang; Wen-Chien Ko; Kun-Yen Huang; Chih-Lung Lee; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.

Authors:  I Chopra; M Roberts
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

3.  The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group.

Authors:  R L Shapiro; S Altekruse; L Hutwagner; R Bishop; R Hammond; S Wilson; B Ray; S Thompson; R V Tauxe; P M Griffin
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

Review 4.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006.

Authors:  Amy M Dechet; Patricia A Yu; Nana Koram; John Painter
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

6.  Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline.

Authors:  J H Bowdre; J H Hull; D M Cocchetto
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

7.  Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.

Authors:  Dana Maglio; Christine Ong; Mary Anne Banevicius; Qiuming Geng; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

8.  Multi-site analysis reveals widespread antibiotic resistance in the marine pathogen Vibrio vulnificus.

Authors:  Craig Baker-Austin; J V McArthur; Angela H Lindell; Meredith S Wright; R Cary Tuckfield; Jan Gooch; Liza Warner; James Oliver; Ramunas Stepanauskas
Journal:  Microb Ecol       Date:  2008-07-19       Impact factor: 4.552

9.  Antibiotic use for Vibrio infections: important insights from surveillance data.

Authors:  Kam Cheong Wong; Anthony M Brown; Georgina M Luscombe; Shin Jie Wong; Kumara Mendis
Journal:  BMC Infect Dis       Date:  2015-06-11       Impact factor: 3.090

Review 10.  Distribution of Fatal Vibrio Vulnificus Necrotizing Skin and Soft-Tissue Infections: A Systematic Review and Meta-Analysis.

Authors:  Kuo-Chin Huang; Hsu-Huei Weng; Tien-Yu Yang; Te-Sheng Chang; Tsan-Wen Huang; Mel S Lee
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more
  8 in total

1.  Late-onset Vibrio vulnificus septicemia without cirrhosis.

Authors:  Michelle T Lee; An Q Dinh; Stephanie Nguyen; Gus Krucke; Truc T Tran
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-28

Review 2.  Epidemiology, pathogenetic mechanism, clinical characteristics, and treatment of Vibrio vulnificus infection: a case report and literature review.

Authors:  Fei Leng; Shilong Lin; Wei Wu; Jincheng Zhang; Jieqiong Song; Ming Zhong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-19       Impact factor: 3.267

3.  In Vitro Synergy and In Vivo Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.

Authors:  Seong Eun Kim; Hee Kyung Kim; Su-Mi Choi; Yohan Yu; Uh Jin Kim; Kalifa Sanneh Darboe; Seung-Ji Kang; Kyung-Hwa Park; Gaeun Kang; Young Ran Kim; Joon Haeng Rhee; Sook-In Jung; Hee-Chang Jang
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  A case of Vibrio vulnificus related wound infection diagnosed by next-generation sequencing.

Authors:  Linhui Li; Lingyan Wang; Chunhong Zhang; Peng Chen; Xu Luo
Journal:  IDCases       Date:  2019-01-24

5.  Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis.

Authors:  Seong Eun Kim; Sung Un Shin; Tae Hoon Oh; Uh Jin Kim; Kalifa Sanneh Darboe; Seung-Ji Kang; Hee-Chang Jang; Sook-In Jung; Hee-Young Shin; Kyung-Hwa Park
Journal:  PLoS Negl Trop Dis       Date:  2019-06-12

6.  Vibrio vulnificus infection attributed to bee sting: a case report.

Authors:  Jie-Heng Liang; Wen-Huan Liang; Yun-Qi Deng; Zhi-Gang Fu; Jun-Li Deng; Yong-Hua Chen
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

7.  Vibrio vulnificus necrotizing fasciitis with sepsis presenting with pain in the lower legs in winter: a case report.

Authors:  Weihua Di; Jing Cui; Hui Yu; Xiao Cui; Huanlan Sa; Zhong Fu; Bingjin Fu; Guofeng Guan; Rui Du; Cuijie Shao; Yong Gao
Journal:  BMC Infect Dis       Date:  2022-08-04       Impact factor: 3.667

Review 8.  Vibrio vulnificus infection: a persistent threat to public health.

Authors:  Na Ra Yun; Dong-Min Kim
Journal:  Korean J Intern Med       Date:  2018-06-15       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.